Lifeward Announces New ReWalk® Data Presented at ASIA 2026 Conference Demonstrating a Comprehensive Longitudinal Safety Analysis for a Powered Exoskeleton

Global data since 2013 show just 3% lifetime fracture prevalence, declining to 0.3% over the past six y**ears

Zero fractures reported across 97 German users since 2018, spanning broad patient profiles and bone health conditions

Findings reinforce safety profile and support expanded adoption of ReWalk for spinal c**ord injury mobility

Lifeward CEO Mark Gr**ant addressed the 53**rd ASIA Annual Scientific Meeting audience with a speech regarding Lifeward and its vision for restoring full function to people living with spinal cord injuries

HUDSON, Mass., and YOKNEAM ILLIT, Israel, May 04, 2026 (GLOBE NEWSWIRE) -- LifewardLtd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced the presentation of new clinical data on the ReWalk®Personal Exoskeleton at the American Spinal Injury Association (ASIA) 2026 Annual Scientific Meeting, which took place in San Antonio, Texas on April 24 – 26, 2026.

The poster presentation titled “Prevalence, Location, and Other Data Regarding Lower Extremity Fractures during Clinical Application of the ReWalk Exoskeleton 2013-2025” highlights over a decade of real-world data evaluating the prevalence and characteristics of lower extremity fractures associated with ReWalk use. The results demonstrate a consistently favorable and improving safety profile, reinforcing confidence in the device among clinicians, patients and caregivers.

While exoskeletons have been in use for mobility and increased activity in spinal cord injury for over a decade, evaluations of risk with their clinical application have been limited relatively rare. Lifeward’s clinical study and findings represent a comprehensive longitudinal safety analysis of powered exoskeleton use in spinal cord injury to date. The near elimination of fractures in recent years, particularly in a real-world national cohort, supports the growing clinical consensus that exoskeleton-assisted walking can be both effective and safe when properly implemented.

“These new data are an important milestone for Lifeward and our ReWalk powered exoskeleton, as well as for the broader field of exoskeleton-assisted mobility,” said Mark Grant, Lifeward’s Chief Executive Officer. “We are seeing low rates of adverse events globally and a clear and sustained improvement in safety over time, culminating in zero fractures in Germany since 2018. That’s a powerful signal reflecting our commitment to continued advancements in device technology, combined with refined patient and provider training, translating directly into better outcomes for patients. These results strengthen the case for broader adoption of ReWalk as a standard of care option to support and rehabilitate individuals with spinal cord injury.”

The data presented analyzed two complementary datasets: 1) Global dataset (2013–2025) evaluated prevalence and location (anatomical and geographical) of lower extremity fractures worldwide across all ReWalk versions; and 2) Germany registry dataset (2018–2025) examined detailed clinical, device use, and bone health data across a diverse population of ReWalk users. Together, these datasets provide both large-scale longitudinal insight and deep patient-level context, offering a comprehensive view of safety outcomes.

Key Findings

• Low overall fracture prevalence: Only 3% of all prescribed devices since 2013 were associated with lower extremity fractures globally.
• Significant improvement over time: Fracture incidence declined to just 0.3% over the past six years (2020–2025).
• Zero fractures in Germany since 2018: Among 97 users tracked over eight years, no fractures were reported despite a wide variation in patient characteristics, activity levels, and bone density.
• Broad patient applicability: The German cohort included individuals with ages ranging from 22 to 69, with time since injury spanning 3 to 53 years, bone density ranging from normal to osteoporotic, and annual usage ranging from hundreds to hundreds of thousands of steps.

The data also showed that earlier years accounted for the vast majority of fracture events, with 87% occurring between 2014 and 2019, suggesting meaningful improvements in device design, training protocols, and patient selection over time.

About Lifeward

Lifeward designs, develops, and commercializes life-changing solutions that span the continuum of restorative healthcare and recovery, delivering proven functional and health benefits in clinical settings as well as in the home and community. Our mission at Lifeward is to relentlessly drive innovation to change the lives of individuals with physical limitations or disabilities. We are committed to delivering groundbreaking solutions that empower individuals to do what they love. The Lifeward portfolio features innovative products including the ReWalk Exoskeleton, the AlterG Anti-Gravity system, the MyoCycle FES System, and the ReStore Exo-Suit.

Founded in 2001, Lifeward has operations in the United States, Israel, and Germany. For more information on the Lifeward mission and product portfolio, please visit GoLifeward.com.

Lifeward®, ReWalk®, ReStore® and Alter G® are registered trademarks of Lifeward Ltd. and/or its affiliates.